There are currently 127 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Autism participants are New York, Florida, California and Ohio.
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829
Recruiting
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
02/05/2024
Locations: Cleveland State University, Cleveland, Ohio
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Register for Updates
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Novartis Investigative Site, Birmingham, Alabama +107 locations
Conditions: Multiple Sclerosis
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/22/2024
Locations: Alabama Neurology Associates Site Number : 8400115, Birmingham, Alabama +25 locations
Conditions: Multiple Sclerosis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +50 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis
NCT02486562
Recruiting
iConquerMS™ is a research initiative developed by and for people with multiple sclerosis (MS) to contribute their health data and ideas to advance and accelerate research into MS.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/18/2024
Locations: Accelerated Cure Project, Waltham, Massachusetts
Conditions: Multiple Sclerosis
Register for Updates
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
All
Ages:
99 years and below
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
MitoQ for Fatigue in Multiple Sclerosis (MS)
NCT04267926
Recruiting
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/18/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Multiple Sclerosis, Fatigue
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05134441
Recruiting
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2024
Locations: Xenoscience, Inc., 21st Century Neurology, Phoenix, Arizona +85 locations
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/17/2024
Locations: Local Institution - 0011, Birmingham, Alabama +33 locations
Conditions: Multiple Sclerosis
Register for Updates
Ukulele Playing to Improve Cognition in People With Multiple Sclerosis: A Feasibility Study
NCT05792176
Recruiting
Over the past 10 years, the rates of multiple sclerosis (MS) have nearly doubled in the United States. This chronic, neuroinflammatory, and neurodegenerative disease is most often diagnosed between the ages of 20-40. Cognitive impairment effects up to 70% of people with MS (PwMS) and has a detrimental impact on mental health, social connections, and employment. Further, up to 50% of PwMS also struggle with depression. Numerous cognitive rehabilitation programs are available to address cognitive... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: University of Texas at Austin, Austin, Texas
Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Register for Updates
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT01931644
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Register for Updates
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2024
Locations: Healthcare Innovations Institute, LLC, Coral Springs, Florida +40 locations
Conditions: Multiple Sclerosis
Register for Updates